COMP-16. CORRELATING MGMT PROTEIN LEVEL WITH TEMOZOLOMIDE RESPONSE IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY

Glioblastoma (GBM) is an aggressive primary brain tumor with median progression-free survival (PFS) of 7 months and median overall survival (OS) of 15 months. Standard treatment at diagnosis consists of surgery, radiation and temozolomide (TMZ). O-6-methylguanine DNA methyltransferase (MGMT) modulat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Yan, Dongyao, Schaff, Lauren, Cecchi, Fabiola, Benz, Steve, Rosenblum, Marc, Hembrough, Todd, Lin, Andrew
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217142/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.271
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares